AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10248153 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific teaching of interviewing techniques
Number of subjects: 0
Study 10248153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 31390002 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR) at 1000 mg twice daily
Number of subjects: 40
Study 31390002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28866974 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte 148
Number of subjects: 8800
Study 28866974 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8800
Study 26240949 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient polypectomy
Number of subjects: 507
Study 26240949 — intervention group
Group type: COMPARATOR
Intervention: Inpatient polypectomy
Number of subjects: 507
Study 26240949 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 507
Study 23984840 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE questionnaire alone
Number of subjects: 30
Study 23984840 — intervention group
Group type: EXPERIMENTAL
Intervention: SCOPE questionnaire with a complementary workshop
Number of subjects: 30
Study 23984840 — intervention group
Group type: COMPARATOR
Intervention: Control arm (care as usual)
Number of subjects: 30
Study 21140163 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal plane proprioception (varus/valgus)
Number of subjects: 17
Study 21140163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal plane proprioception (flexion/extension)
Number of subjects: 17
Study 19786219 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis
Number of subjects: 60
Study 19786219 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure vessel sealing system
Number of subjects: 60
Study 19786219 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel
Number of subjects: 60
Study 16769988 — intervention group
Group type: EXPERIMENTAL
Intervention: EC + G‐CSF
Number of subjects: 506
Study 16769988 — intervention group
Group type: COMPARATOR
Intervention: EC alone
Number of subjects: 506
Study 16769988 — intervention group
Group type: COMPARATOR
Intervention: Schedule 5 G‐CSF
Number of subjects: 506
Study 16769988 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven or four G‐CSF injections
Number of subjects: 506
Study 15497904 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 45
Study 15497904 — intervention group
Group type: COMPARATOR
Intervention: Superficial needle insertion
Number of subjects: 45
Study 15497904 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol
Number of subjects: 45
Study 11672897 — intervention group
Group type: EXPERIMENTAL
Intervention: RIVM hexavalent OMV vaccine (three doses at 0, 2, and 8 months)
Number of subjects: 0
Study 11672897 — intervention group
Group type: EXPERIMENTAL
Intervention: RIVM hexavalent OMV vaccine
Number of subjects: 0
Study 9153693 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment
Number of subjects: 91
Study 9153693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline with standard clinical management
Number of subjects: 91
Study 9153693 — intervention group
Group type: COMPARATOR
Intervention: Drug placebo with standard clinical management
Number of subjects: 91
Study 9153693 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 91
Study 8484513 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O)
Number of subjects: 40
Study 8484513 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 40
Study 2974302 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE (Gore‐Tex CV patch)
Number of subjects: 71
Study 2974302 — intervention group
Group type: COMPARATOR
Intervention: Autogenous saphenous vein
Number of subjects: 71
Study 2974302 — intervention group
Group type: COMPARATOR
Intervention: Dacron velour (Sauvage Filamentous)
Number of subjects: 71
Study 29503083 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular strategy
Number of subjects: 502
Study 29503083 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 502
Study 29503083 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of three trials (IMPROVE, AJAX, ECAR)
Number of subjects: 502
Study 25757867 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 105
Study 25757867 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 105
Study 25757867 — intervention group
Group type: EXPERIMENTAL
Intervention: Early decrease of 24h proteinuria <0.5g/day at 3, 6, and 12 months
Number of subjects: 105
Study 24102655 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal peer-review training for nurses
Number of subjects: 0
Study 21258804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack therapy
Number of subjects: 44
Study 21258804 — intervention group
Group type: COMPARATOR
Intervention: Hot pack therapy
Number of subjects: 44
Study 20102667 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (β-noradrenergic antagonist)
Number of subjects: 0
Study 20102667 — intervention group
Group type: COMPARATOR
Intervention: Visual control regions
Number of subjects: 0
Study 18825580 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAG (Physical Activity Guide to Healthy Active Living)
Number of subjects: 130
Study 18825580 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire only)
Number of subjects: 130
Study 16377919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF) 0.15-0.3 mg/kg
Number of subjects: 91
Study 16377919 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine (LID)
Number of subjects: 91
Study 16377919 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifekalant (NIF)
Number of subjects: 91
Study 12822874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b + Ribavirin (1000-1200 mg/day for 48 weeks)
Number of subjects: 125
Study 12822874 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha2b + Placebo
Number of subjects: 125
Study 12822874 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b + Ribavirin
Number of subjects: 125
Study 11402829 — intervention group
Group type: EXPERIMENTAL
Intervention: Viscoelastics (ophthalmic viscosurgical device, OVD)
Number of subjects: 11
Study 9414366 — intervention group
Group type: EXPERIMENTAL
Intervention: Laptop computer
Number of subjects: 0
Study 9414366 — intervention group
Group type: COMPARATOR
Intervention: Desktop computer
Number of subjects: 0
Study 8428323 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate 600 mg/m2 orally daily for up to 2 years
Number of subjects: 437
Study 8428323 — intervention group
Group type: EXPERIMENTAL
Intervention: estramustine phosphate adjuvant
Number of subjects: 437
Study 8428323 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant estramustine phosphate
Number of subjects: 437
Study 8428323 — intervention group
Group type: EXPERIMENTAL
Intervention: adjuvant cyclophosphamide 1 g/m2 intravenously every 3 weeks for 2 years
Number of subjects: 437
Study 8428323 — intervention group
Group type: COMPARATOR
Intervention: no adjuvant therapy
Number of subjects: 437
Study 2892864 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at 10 PM
Number of subjects: 20
Study 2892864 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 20
Study 28003041 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat consumption group (50 g/day oats)
Number of subjects: 52
Study 28003041 — intervention group
Group type: COMPARATOR
Intervention: Control group (recommended to reduce intake of dietary protein, phosphorus, sodium and potassium)
Number of subjects: 52
Study 28719294 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeleton-binding protein 1 (SBP1)
Number of subjects: 0
Study 28719294 — intervention group
Group type: EXPERIMENTAL
Intervention: REX1
Number of subjects: 0
Study 28719294 — intervention group
Group type: EXPERIMENTAL
Intervention: PHISTb
Number of subjects: 0
Study 28719294 — intervention group
Group type: EXPERIMENTAL
Intervention: Established markers (18S DNA and rRNA, Pfs25 mRNA)
Number of subjects: 0
Study 28719294 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo clinical trial samples
Number of subjects: 0
Study 26181703 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Number of subjects: 336
Study 24012319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 200 mg tablets twice daily
Number of subjects: 258
Study 24012319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 24012319 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 258
Study 21128152 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally derived metaphor (i.e., sex of a baby)
Number of subjects: 64
Study 21128152 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard metaphor (i.e., flip of a coin)
Number of subjects: 64
Study 21128152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-literacy definition
Number of subjects: 64
Study 21128152 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention (moderator)
Number of subjects: 64
Study 21128152 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affective response to the randomization message
Number of subjects: 64
Study 19061374 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Dopa (200 mg)
Number of subjects: 12
Study 19061374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17333809 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 2 x 200 mg/day for 1 week
Number of subjects: 6
Study 17333809 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel, single dose, 40 mg/kg body weight
Number of subjects: 6
Study 17333809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytetracycline, 15 mg in 0.5 mL medium (in vitro)
Number of subjects: 6
Study 17333809 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Myrtus communis (in vitro)
Number of subjects: 6
Study 17333809 — intervention group
Group type: EXPERIMENTAL
Intervention: Extract of Eucalyptus comaldensis, 50 mg in 0.1 mL medium (in vitro)
Number of subjects: 6
Study 14727945 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis
Number of subjects: 78
Study 14727945 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 78
Study 10724022 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam, 200 mg three times daily for 3 days
Number of subjects: 216
Study 10724022 — intervention group
Group type: COMPARATOR
Intervention: cephalexin, 250 mg four times daily for 7 days
Number of subjects: 216
Study 8730167 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against 10% sodium lauryl sulfate (SLS)
Number of subjects: 20
Study 8730167 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against undiluted toluene (TOL)
Number of subjects: 20
Study 8730167 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against 1% sodium hydroxide (NaOH) and 30% lactic acid (LA)
Number of subjects: 20
Study 8730167 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective Creams (PCs) against SLS and NaOH
Number of subjects: 20
Study 29568693 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 40
Study 29568693 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study 28764800 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the neonatal trial
Number of subjects: 0
Study 26596013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection as initial treatment (group A)
Number of subjects: 63
Study 26596013 — intervention group
Group type: COMPARATOR
Intervention: Systemic hormone therapy (group B)
Number of subjects: 63
Study 26596013 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic dexamethasone injection as salvage treatment (group C)
Number of subjects: 63
Study 24198750 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet supplemented with numerical data on cancer risk and effects of HPV vaccination
Number of subjects: 105
Study 24198750 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflet on HPV vaccination
Number of subjects: 105
Study 20617919 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraffin baths 80% wax with 20% topical analgesic (PTA)
Number of subjects: 0
Study 20617919 — intervention group
Group type: COMPARATOR
Intervention: Paraffin baths only (PO) (100% wax)
Number of subjects: 0
Study 18302501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min of jumping activity in place of regular physical education (PE) warm up
Number of subjects: 99
Study 18302501 — intervention group
Group type: COMPARATOR
Intervention: Usual PE warm-up activities
Number of subjects: 99
Study 16292564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surgery (total colectomy or restorative proctocolectomy)
Number of subjects: 0
Study 16292564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intervention for endometrium and stomach
Number of subjects: 0
Study 12462285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 482
Study 12462285 — intervention group
Group type: COMPARATOR
Intervention: All active treatments
Number of subjects: 482
Study 10336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (MOR) 2.5, 5, and 10 mg/70 kg
Number of subjects: 16
Study 10336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM) 0.33, 0.65, and 1.3 mg/70 kg
Number of subjects: 16
Study 10336539 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (MEP) 17.5, 35, and 70 mg/70 kg
Number of subjects: 16
Study 10336539 — intervention group
Group type: COMPARATOR
Intervention: Saline (SAL)
Number of subjects: 16
Study 8571416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22071
Study 2021128 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty Fish (FF)
Number of subjects: 28
Study 2021128 — intervention group
Group type: COMPARATOR
Intervention: Red Meat (RM)
Number of subjects: 28
Study 7172618 — intervention group
Group type: EXPERIMENTAL
Intervention: Clients who chose their own therapist after viewing a slide/sound presentation.
Number of subjects: 42
Study 7172618 — intervention group
Group type: COMPARATOR
Intervention: Clients assigned to a therapist by the clinical director after viewing the presentation.
Number of subjects: 42
Study 7172618 — intervention group
Group type: COMPARATOR
Intervention: Clients assigned to a therapist by the clinical director without viewing the presentation.
Number of subjects: 42
Study 30058511 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued antipsychotic treatment
Number of subjects: 189
Study 30058511 — intervention group
Group type: COMPARATOR
Intervention: Continued antipsychotic treatment
Number of subjects: 189
Study 28720617 — intervention group
Group type: EXPERIMENTAL
Intervention: Relatives Education And Coping Toolkit (REACT)
Number of subjects: 666
Study 28720617 — intervention group
Group type: COMPARATOR
Intervention: Resource Directory (RD) only
Number of subjects: 666
Study 27531506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified, multifactorial treatment (mean treatment duration 7.8 years)
Number of subjects: 160
Study 27531506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified, multifactorial treatment
Number of subjects: 160
Study 27531506 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 160
Study 24418924 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D video preparation
Number of subjects: 84
Study 24418924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D video preparation
Number of subjects: 84
Study 24418924 — intervention group
Group type: COMPARATOR
Intervention: Guide preparation
Number of subjects: 84
Study 22616081 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdebrider
Number of subjects: 60
Study 19387389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotorized treadmill exercise at varying speeds (3.22, 4.83, 6.44, 8.05, 9.66, and 11.27 km/h)
Number of subjects: 20
Study 19387389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmotorized treadmill exercise
Number of subjects: 20
Study 19387389 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise test on a standard treadmill
Number of subjects: 20
Study 17365741 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol cigarettes
Number of subjects: 5887
Study 17365741 — intervention group
Group type: COMPARATOR
Intervention: Plain cigarettes
Number of subjects: 5887
Study 15535489 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine 30 microg/kg
Number of subjects: 93
Study 15535489 — intervention group
Group type: EXPERIMENTAL
Intervention: lignocaine 2% (40 mg)
Number of subjects: 93
Study 15535489 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 93
Study 11674912 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% dextrose solution
Number of subjects: 71
Study 11674912 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 71
Study 11674912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 71
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 4 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 8 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 12 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 16 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 10 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (>= 4 mg/day)
Number of subjects: 141
Study 9477007 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 or 4 mg/day
Number of subjects: 141
Study 9477007 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (optimal dose)
Number of subjects: 141
Study 8200988 — intervention group
Group type: EXPERIMENTAL
Intervention: IgA anti-CD3 mAb (T3.A)
Number of subjects: 20
Study 8200988 — intervention group
Group type: COMPARATOR
Intervention: IgG2a anti-CD3 mAb (T3.G2a)
Number of subjects: 20
Study 3363287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg/day for 3 days
Number of subjects: 6
Study 30419120 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (3 days, twice daily)
Number of subjects: 1126
Study 30419120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 days, twice daily)
Number of subjects: 1126
Study 27848159 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent chemotherapy (Group R)
Number of subjects: 120
Study 27848159 — intervention group
Group type: COMPARATOR
Intervention: No recent chemotherapy (Group O)
Number of subjects: 120
Study 27848159 — intervention group
Group type: EXPERIMENTAL
Intervention: Entire cohort
Number of subjects: 120
Study 25172089 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month home-based exercise programme
Number of subjects: 67
Study 25172089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 67
Study 23760292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet
Number of subjects: 40
Study 23760292 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium/low-potassium diet
Number of subjects: 40
Study 23760292 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet with furosemide infusion
Number of subjects: 40
Study 23760292 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum sodium/potassium diet
Number of subjects: 40
Study 21226788 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory of planned behaviour (TPB) cognitions
Number of subjects: 365
Study 21226788 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective energy expenditure measurement
Number of subjects: 365
Study 18164013 — intervention group
Group type: EXPERIMENTAL
Intervention: CETP lowering B2 allele and HL lowering LIPC-T allele
Number of subjects: 792
Study 18164013 — intervention group
Group type: EXPERIMENTAL
Intervention: B1B1/CC genotype
Number of subjects: 792
Study 18164013 — intervention group
Group type: EXPERIMENTAL
Intervention: B2B2/TT genotype
Number of subjects: 792
Study 18164013 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery lumen diameter loss
Number of subjects: 792
Study 17062300 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol tablet containing sodium bicarbonate (PSC)
Number of subjects: 241
Study 17062300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 241
Study 12702521 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, Methotrexate and 5-Fluorouracil (CMF)
Number of subjects: 777
Study 12702521 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-Cyclophosphamide at intermediate doses (EC)
Number of subjects: 777
Study 12702521 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-Cyclophosphamide at full doses (HEC)
Number of subjects: 777
Study 10547215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30 microg q.i.d.)
Number of subjects: 13
Study 10547215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Total BDI scores
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Body image distortion
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of appetite
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Crying
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessimism
Number of subjects: 245
Study 8722731 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure
Number of subjects: 245